MBE Wealth Management LLC Has $205,000 Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

MBE Wealth Management LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 69.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 394 shares of the medical research company’s stock after selling 884 shares during the quarter. MBE Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $205,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Patrick M Sweeney & Associates Inc. raised its holdings in Thermo Fisher Scientific by 2.1% in the 4th quarter. Patrick M Sweeney & Associates Inc. now owns 1,066 shares of the medical research company’s stock worth $555,000 after acquiring an additional 22 shares during the period. Curbstone Financial Management Corp bought a new position in Thermo Fisher Scientific in the 4th quarter worth $685,000. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. YHB Investment Advisors Inc. raised its holdings in Thermo Fisher Scientific by 0.4% in the 4th quarter. YHB Investment Advisors Inc. now owns 46,450 shares of the medical research company’s stock worth $24,165,000 after acquiring an additional 200 shares during the period. Finally, Nilsine Partners LLC raised its holdings in Thermo Fisher Scientific by 4.6% in the 4th quarter. Nilsine Partners LLC now owns 10,665 shares of the medical research company’s stock worth $5,548,000 after acquiring an additional 473 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 34,850 shares of company stock worth $19,123,197. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. TD Cowen lifted their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Bernstein Bank boosted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Morgan Stanley dropped their price objective on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Finally, Bank of America dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $583.43 on Tuesday. The firm has a market cap of $223.16 billion, a PE ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company’s 50-day moving average price is $533.60 and its two-hundred day moving average price is $569.81.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.